Does the EQ-5D reflect lost earnings?

PharmacoEconomics

Volumn 30, Issue 1, 2012, Pages 47-61

  Tilling, Carl ^a   Kro, Marieke ^b   Tsuchiya, Aki ^a,c   Brazier, John ^a   Exel, Job ^b   Brouwer, Werner ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EQ 5D; HEALTH CARE COST; HEALTH STATUS; HEALTH SURVEY; HUMAN; INCOME; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 83455236581     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11539910-000000000-00000     Document Type: Article

References (24)

1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (N1618). London: NICE, 2008 [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune 2008.pdf [Accessed 2008 Nov 1]
2. College voor Zorgverzekeringen. Dutch guidelines for pharmacoeconomic research [report ref. CURE/cuo.228/2]. Amstelveen: CVZ, 1999 [online].Available from URL:www.ispor.org/PEguidelines/source/PE-guidelines-english-Netherlands.pdf [Accessed 2008 Nov 1]
3. Dolan P. Modelling valuations for EuroQol health states. Med Care 1997; 35 (11): 1095-108 (Pubitemid 127453463)
4. Lamers LM, McDonnell J, Stalmeier PFM, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuations studies. Health Econ 2006; 15 (10): 1121-32 (Pubitemid 44596379)
5. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ- 5D health states: development and testing of the D1 valuation model. Med Care 2005; 43 (3): 203-20 (Pubitemid 40353904)
6. Greiner W, Claes C, Buschbach JJV, et al. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005; 6 (2): 124-30 (Pubitemid 40905009)
7. Brouwer WBF, Koopmanschap MA, Rutten FHH, et al. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253-9 (Pubitemid 27296589)
8. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
9. Tilling CJ, Krol M, Tsuchiya A, et al. In or out? Income losses in health state valuations: a review. Value Health. 2010; 13 (2): 298-305
10. Weisbrod BA. The valuation of human capital. J Polit Econ 1961; 69 (5): 425-36
11. Rice D, Cooper B. The economic value of human life. Am J Public Health 1967; 57: 1954-66
12. Koopmanschap MA, van Ineveld B. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005-10
13. Krol M, Brouwer WBF, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics 2006; 24 (4): 401-14
14. Davidson T, Levin LA. Do individuals consider expected income when valuing health states? Int J Technol Assess Health Care 2008; 24 (4): 488-94
15. Brouwer WBF, Grootenboer S, Sendi P. The incorporation of income and leisure in health state valuations when the measure is silent: an empirical inquiry into the sound of silence. Med Decis Making 2009; 29 (4): 503-12
16. Krol M, Sendi P, Brouwer WBF. Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises. Value Health 2009; 12 (10): 172-80
17. Meltzer D, Weckerle CE, Chang LM. Do people consider financial effects in answering quality of life questions? [abstract]. Med Decis Making 1999; 19: 517
18. Sendi P, Brouwer WBF. Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ 2005; 14: 643-7 (Pubitemid 40797038)
19. Myers J, McCabe S, Gohmann S. Quality-of-life assessment when there is a loss of income. Med Decis Making 2007; 27: 27-33 (Pubitemid 46068149)
20. Richardson J, Peacock S, Lezzi A. Do quality-adjusted life years take account of lost income? Evidence from an Australian survey. Eur J Health Econ 2009; 10 (1): 103-9
21. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002; 11 (4): 341-53 (Pubitemid 34578418)
22. Attema AE, Brouwer WBF. The correction for utility scores for utility curvature using a risk free utility elicitation method. J Health Econ 2009; 28 (1): 234-43
23. Stata [computer program]. Version 9. College Station (TX): StataCorp, 2005
24. van Nooten FE, Koolman X, Brouwer WBF. The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ; 2009; 18 (5): 549-58